Article and Video CATEGORIES

Cancer Journey

Search By

Ramy Sedhom, MD, is a Medical Oncology Fellow at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland.

He is interested in Supportive and Palliative Care for patients across the cancer continuum - from a clinical, research, and policy perspective. Following his oncology training, he will be pursuing a clinical fellowship in Hospice and Palliative Care.

Bladder Cancer Series Hosted by Dr. Sedhom, with Dr. Petros Grivas - Muscle Invasive Bladder Cancer
Bladder Cancer Series Hosted by Dr. Sedhom, with Dr. Petros Grivas - Muscle Invasive Bladder Cancer
Author
Ramy Sedhom, MD, GRACE Guest Faculty
Image
We are excited to bring you new information on our Bladder Cancer Program, hosted by Ramy Sedhom, MD.

For this video, Dr. Ramy Sedhom introduces us to Dr. Petros Grivas, from the University of Washington and the Fred Hutchinson Cancer Center.  For more information on Dr. Grivas, please visit his bio here

In this video, Drs. Sedhom and Grivas discuss muscle invasive bladder cancer.

If you have questions or comments, please feel free to join the conversation at https://cancergrace.org/forums/bladder-cancer.

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
That's beautiful Linda…
By JanineT GRACE … on
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on